Factors associated with the emergence of resistance mutations in patients failing dual or triple-integrase inhibitors-based regimen in a French national survey

European Meeting on HIV & Hepatitis 2020

HIV DNA drug resistance genotyping, based on illumina sequencing, as decisional marker for cart opimisation in clinical practice: added value, gaps and future directions

European Meeting on HIV & Hepatitis 2020

High efficacy after switching to integrase strand transfer inhibitors (INSTI) in PLWH with undetectable viremia and past virological failure and/or resistance

European Meeting on HIV & Hepatitis 2020

Emergence and Persistence of Integrase Mutation T97A Selected by Dolutegravir

European Meeting on HIV & Hepatitis 2020

Evaluation of HIV-1 RNA and DNA mutational load in HIV-1 infected heavily treatment-experienced patients harbouring multi-drug resistant strains

European Meeting on HIV & Hepatitis 2020

Long-term Bictegravir and Dolutegravir Resistance Selections Initiated with HIV-1 Containing M184V in Reverse Transcriptase

European Meeting on HIV & Hepatitis 2020

Molecular analysis of HCV subtype 3a dispersal patterns among inmates in Greece: HCV transmissions are not related to incarceration

European Meeting on HIV & Hepatitis 2020

Highly sensitive digital droplet PCR assay allows to reveal cryptic HBV replication in anti-HBc positive/HBsAg negative patients with HIV infection.

European Meeting on HIV & Hepatitis 2020

Susceptibility to HIV-1 integrase inhibitors in HIV-1 sub-subtype A6 isolates

European Meeting on HIV & Hepatitis 2020

Residual phenotypic susceptibility to second generation NNRTI in multidrug resistant HIV-1 from the PRESTIGIO Registry

European Meeting on HIV & Hepatitis 2020

Two-drug regimen (2DR) for initial HIV treatment? – Lessons learned from 20 years RESINA cohort

European Meeting on HIV & Hepatitis 2020

Dynamics of HIV-1 transmission clusters in North and Central Italy over the years 2012-2019

European Meeting on HIV & Hepatitis 2020

Transmitted drug resistance to integrase based first-line HIV antiretroviral treatment in the MeditRes HIV collaboration

European Meeting on HIV & Hepatitis 2020

Exploring Molecular Characteristics and Evolutionary Dynamics of the HIV-1 Epidemic in Montenegro Through Phylogenetic Analyses

European Meeting on HIV & Hepatitis 2020

Prevalence and spatiotemporal dynamics of the HIV-1 circulating recombinant form 03_AB (CRF03_AB) in the former Soviet Union

European Meeting on HIV & Hepatitis 2020

Cabotegravir + Rilpivirine Every 2 Months Is Noninferior to Monthly: ATLAS-2M Study

European Meeting on HIV & Hepatitis 2020

Short- and long-term direct medical costs of late and very late HIV presentation

European Meeting on HIV & Hepatitis 2020

Treatment outcome among people living with HIV starting first-line rapid or GRT guided ART from 2015 to 2018

European Meeting on HIV & Hepatitis 2020

Evaluation of HIV-1 tropism in multidrug-resistant cART failing patients

European Meeting on HIV & Hepatitis 2020

DTG+3TC vs DTG+TDF/FTC (GEMINI1&2): Confirmed Virologic Withdrawals Through Week 96

European Meeting on HIV & Hepatitis 2020

Emergence of Resistance in HIV-1 Integrase following Dolutegravir Treatment in Participants Aged 4 Weeks to <18 Years: Results from the IMPAACT P1093 Study

European Meeting on HIV & Hepatitis 2020

Assessment of Genotypic Patterns Associated with HIV-1 Sensitivity to Ibalizumab

European Meeting on HIV & Hepatitis 2020

In vitro activity of Islatravir against HIV-1 mutants harboring multiple NRTI resistance mutations

European Meeting on HIV & Hepatitis 2020

Detection in HIV proviral DNA of drug resistance mutations in patients with low permanent viral loads

European Meeting on HIV & Hepatitis 2020